Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Salarius Pharmaceuticals ( (SLRX) ) just unveiled an update.
Salarius Pharmaceuticals, Inc. has been granted an extension by the Nasdaq Hearings Panel to regain compliance with Nasdaq’s Equity Standard by October 20, 2025. The company had previously received a delisting notice due to non-compliance with the Minimum Bid Price Requirement and the Equity Standard. Salarius executed a 1-for-15 reverse stock split on August 15, 2025, and expects to meet the Minimum Bid Price Requirement by August 29, 2025. The extension is contingent on achieving scheduled milestones and notifying Nasdaq of these achievements.
Spark’s Take on SLRX Stock
According to Spark, TipRanks’ AI Analyst, SLRX is a Underperform.
Salarius Pharmaceuticals exhibits significant financial instability, characterized by declining revenues and persistent losses, which severely impacts its stock score. Technically, the stock is on a bearish trend, trading below major moving averages, with negative momentum indicators. The valuation is further weakened by a negative P/E ratio and absence of dividend, making it unattractive to value or income investors. Overall, the stock is highly risky and requires cautious consideration.
To see Spark’s full report on SLRX stock, click here.
More about Salarius Pharmaceuticals
Average Trading Volume: 223,939
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.94M
For a thorough assessment of SLRX stock, go to TipRanks’ Stock Analysis page.